Roy M Fleischmann, MD
Roy Fleischmann, MD, is Clinical Professor of Medicine at the University of Texas Southwestern Medical Center, Dallas, and co-Medical Director of the Metroplex Clinical Research Center in Dallas. He is in the private practice of rheumatology in Dallas, TX. Dr Fleischmann graduated from Stuyvesant High School in New York City and Columbia College in New York City. He received his MD from the State University of New York, Downstate Medical Center, and completed his residency in Internal Medicine at Mount Sinai Medical Center, New York. His fellowship in rheumatology was completed at the College of Physicians and Surgeons of Columbia University, New York under the mentoring of Carwile Leroy. He is board certified in internal medicine with subspecialty certification in rheumatology.
Following his fellowship he joined the faculty of the College of Physicians and Surgeons of Columbia University where he conducted both basic and clinical research, taught fellows, residents and students and had a limited private practice. He was recruited to Dallas, Texas in 1975 to join the Division of Rheumatology at the University of Texas Southwestern Medical Center, Dallas, by Professor Morris Ziff. He started a private practice in rheumatology on the campus of the University in 1978, and has been active in the teaching program of the University with respect to mentoring students, residents and fellows and establishing a clinical research center focusing on the development of new drugs for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, scleroderma, gout and osteoarthritis. He currently employs 16 board certified rheumatologists and 6 mid-level practitioners at his private practice. It is the largest group of rheumatology private practitioners in the State of Texas with multiple offices through-out the Dallas-Fort Worth Metroplex.
He formed the Metroplex Clinical Research Center in 1984 which has conducted numerous trials in all aspects of rheumatology including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, scleroderma, gout and osteoarthritis. The Center conducts phase I-IV clinical trials, focusing on phase I-III. Over the years, more than 1000 clinical studies have been performed.
Dr Fleischmann has authored approximately 200 manuscripts, focusing on the management of rheumatoid arthritis, which have been published in peer-reviewed journals and he has authored over 350 abstracts which have been presented at rheumatology meetings worldwide. He has been an active teacher in the Fellowship program of the University of Texas Southwestern Medical center. Dr Fleischmann has helped design, implement and report the results of studies on virtually every medication approved for use in the treatment of rheumatoid arthritis. He has been an invited speaker at many international rheumatology meetings and symposia worldwide in which he has discussed the diagnosis and management of rheumatoid arthritis. Dr Fleischmann was an early proponent of the aggressive treatment of rheumatoid arthritis and the importance of measuring disease activity in order to help guide treatment decisions.
He is a Master of the American College of Rheumatology, a former President of the Texas Rheumatism Association, and a former President of the Dallas–Fort Worth Rheumatism Association. He has served on the finance committee of the American College of Rheumatology and the Fund-Raising Committee of the Research and Education Foundation of the ACR. He has presented frequently at the ACR and EULAR annual meetings and has conducted Meet the Expert sessions. He is a reviewer for many peer-reviewed journals including Arthritis Rheumatism, the Annals of Rheumatic Disease and the Journal of Rheumatology. Dr Fleischmann was an Associate Editor for Rheumatology (Oxford), is on the Editorial Board of Rheumatology (Oxford) and the Editor of Rheumatology and Therapy. He was selected as being in the top 5% of reviewers for Arthritis and Rheumatology.
Dr Fleischmann has been recognized as an outstanding clinician by D magazine and Texas Monthly, he has also been selected as one of Americas Best Physicians on numerous occasions.
Consultancy – AbbVie, Amgen, AstraZeneca, BMS, Janssen, Eli Lilly, Pfizer, Regeneron, Sanofi Aventis, UCB, Research funding – AbbVie, Ardea, AstraZeneca, BMS, Boehringer-Ingelheim, GSK, Genentech, Janssen, Eli Lilly, Pfizer, Regeneron, Resolve, Roche, Sanofi Aventis, UCB